Lineage Cell Therapeutics, Inc. Finite-Lived Intangible Assets, Net
Lineage Cell Therapeutics, Inc. (LCTX) had Finite-Lived Intangible Assets, Net of $0 as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization › Intangible Asset, Finite-Lived, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsNet · last filed 2026-03-05
- 2025-12-31: Finite-Lived Intangible Assets, Net $0.00.
- 2025-09-30: Finite-Lived Intangible Assets, Net $0.00.
- 2025-06-30: Finite-Lived Intangible Assets, Net $0.00.
- 2025-03-31: Finite-Lived Intangible Assets, Net $0.00.
| Period end | Finite-Lived Intangible Assets, Net | Finite-Lived Intangible Assets, Net as first filed |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-05 | |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $0.00 10-K · filed 2026-03-05 | |
| 2023-12-31 | $22.00K 10-K · filed 2025-03-10 | |
| 2023-09-30 | $54.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $87.00K 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $119.00K 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $152.00K 10-K · filed 2023-03-09 | |
| 2022-09-30 | $184.00K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $217.00K 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $249.00K 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $282.00K 10-K · filed 2022-03-10 | |
| 2021-09-30 | $314.00K 10-Q · filed 2021-11-10 | |
| 2020-12-31 | $492.00K 10-K · filed 2021-03-11 | |
| 2019-12-31 | $48.25M 10-K · filed 2020-03-12 | |
| 2019-09-30 | $48.75M 10-Q · filed 2019-11-12 | |
| 2019-06-30 | $49.32M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $49.83M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $3.13M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $3.60M 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $5.74M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $6.32M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $6.90M 10-K · filed 2019-03-14 | |
| 2017-09-30 | $7.48M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $8.06M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $8.65M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $10.21M 10-K · filed 2018-03-15 | |
| 2016-09-30 | $10.85M 10-Q · filed 2016-11-04 | |
| 2016-06-30 | $11.49M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $32.28M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $33.59M 10-K · filed 2017-03-16 | |
| 2015-09-30 | $34.91M 10-Q · filed 2015-11-09 | |
| 2015-06-30 | $36.22M 10-Q · filed 2015-08-10 | |
| 2015-03-31 | $37.53M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $38.85M 10-K · filed 2016-03-15 | $38.85M 10-K · filed 2015-03-11 |
| 2014-09-30 | $42.10M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $43.47M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $44.84M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | $46.21M 10-K · filed 2015-03-11 | |
| 2013-09-30 | $18.56M 10-Q · filed 2013-11-12 | |
| 2013-06-30 | $19.20M 10-Q · filed 2013-08-09 | |
| 2013-03-31 | $19.84M 10-Q · filed 2013-05-10 | |
| 2012-12-31 | $20.49M 10-K · filed 2014-03-17 | |
| 2012-09-30 | $21.09M 10-Q · filed 2012-11-09 | |
| 2012-06-30 | $21.65M 10-Q · filed 2012-08-09 | |
| 2011-12-31 | $18.62M 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |